Vitamin K Deficiency Bleeding (VKDB)

01Pathophysiology

Vitamin K is a fat-soluble vitamin that serves as an essential cofactor for the hepatic enzyme gamma-glutamyl carboxylase. This enzyme catalyzes the gamma-carboxylation of glutamic acid residues on coagulation factors II (prothrombin), VII, IX, and X, as well as anticoagulant proteins C and S. Without adequate vitamin K, these factors are synthesized but remain in a functionally inactive form known as PIVKA (Proteins Induced by Vitamin K Absence or Antagonism). These undercarboxylated proteins cannot bind calcium ions and therefore cannot participate in the coagulation cascade on phospholipid surfaces.

Neonates are uniquely vulnerable to vitamin K deficiency for several converging reasons. First, placental transfer of vitamin K is extremely poor, resulting in low stores at birth. Second, the neonatal gut is sterile at the time of delivery, and bacterial colonization (which normally produces vitamin K2/menaquinone) takes days to weeks to establish. Third, breast milk contains very low concentrations of vitamin K (approximately 1-2 mcg/L), far less than formula milk (which is supplemented to approximately 50-60 mcg/L). Fourth, neonatal hepatic enzyme systems are immature, reducing the efficiency of vitamin K-dependent carboxylation.

The reason factor VII is clinically relevant is that it has the shortest half-life among the vitamin K-dependent factors (approximately 6 hours). This explains why the prothrombin time (PT) is the first coagulation parameter to become prolonged in vitamin K deficiency, since the extrinsic pathway depends on factor VII. As the deficiency progresses and factors II, IX, and X are also depleted, the aPTT becomes prolonged as well.

Maternal medications such as phenytoin, carbamazepine, phenobarbital, warfarin, rifampicin, and isoniazid cross the placenta and interfere with vitamin K metabolism or the vitamin K cycle in the fetus, predisposing to the early-onset form of VKDB occurring within the first 24 hours of life.

Cholestatic liver disease (such as biliary atresia) impairs the absorption of fat-soluble vitamins including vitamin K by reducing bile salt delivery to the intestinal lumen, making these infants particularly susceptible to the late-onset form even if they received prophylaxis at birth.

02Classification and Clinical Manifestation

The classic exam scenario for early VKDB involves a neonate born to a mother on anticonvulsant therapy who bleeds within hours of birth. Classic VKDB is the "textbook" presentation: a 3-5-day-old exclusively breastfed infant who did not receive vitamin K, presenting with GI bleeding or umbilical oozing. Late VKDB is the most dangerous and presents as the "6-week-old exclusively breastfed infant with sudden seizures and intracranial hemorrhage."

03Diagnostic Workup

The workup begins with a PT/INR, which is the best initial test because factor VII has the shortest half-life and is depleted first. A prolonged PT in an otherwise well-appearing neonate or young infant, especially one who is exclusively breastfed and did not receive vitamin K prophylaxis, should immediately raise suspicion for VKDB.

The aPTT is ordered alongside the PT. In mild or early vitamin K deficiency, the aPTT may still be normal because factors IX, X, and II have longer half-lives than factor VII. As deficiency worsens, the aPTT also becomes prolonged. The combination of prolonged PT + prolonged aPTT + normal platelet count + normal fibrinogen is the classic laboratory signature of VKDB.

Platelet count and fibrinogen must be checked to exclude disseminated intravascular coagulation (DIC), which is the most important differential in a bleeding neonate. In DIC, platelets and fibrinogen are consumed, D-dimer is elevated, and schistocytes appear on the peripheral smear. None of these findings are present in VKDB.

The most accurate confirmatory test is the measurement of PIVKA-II (des-gamma-carboxy prothrombin), which directly quantifies the undercarboxylated, non-functional form of prothrombin. However, this test has limited availability in many clinical settings.

In practice, the therapeutic trial of vitamin K often serves as both a diagnostic and a treatment step. When vitamin K is administered intravenously, the PT should begin to correct within 2-4 hours and fully normalize by 12-24 hours. This rapid, predictable response is considered virtually diagnostic and is often the most practical confirmatory approach used on exams and in clinical settings.

For any infant presenting with neurological symptoms (seizures, lethargy, bulging fontanelle), emergent neuroimaging (cranial ultrasound as first-line for neonates with an open fontanelle, or CT head for rapid assessment of acute hemorrhage) is indicated to evaluate for intracranial bleeding.

04Management and Treatment

Step 1: Prophylaxis is the foundation. The single most important intervention for VKDB is prevention. All newborns should receive vitamin K1 1 mg IM within the first hour of life. This single injection effectively prevents classic VKDB and substantially reduces the incidence of late VKDB. The intramuscular route is strongly preferred because oral vitamin K has unreliable absorption and requires multiple doses over weeks, with significant risk of non-compliance.

Step 2: Recognize and treat active bleeding. When a neonate or infant presents with bleeding and the laboratory profile suggests VKDB (prolonged PT, normal platelets, normal fibrinogen), the next best step is to administer vitamin K1 1-2 mg slow IV. The intravenous route is chosen over intramuscular in a bleeding patient because an intramuscular injection into a coagulopathic infant can cause a large hematoma. The IV infusion must be given slowly over at least 10-20 minutes because rapid intravenous administration of vitamin K carries a risk of anaphylactoid reaction (hypotension, bronchospasm, cardiovascular collapse) due to the solubilizing agents in the formulation.

Step 3: Bridge therapy for severe hemorrhage. Vitamin K takes approximately 2-4 hours to produce functional clotting factors even when given intravenously. For infants with life-threatening bleeding (large-volume GI hemorrhage, active intracranial hemorrhage), this delay is unacceptable. Fresh Frozen Plasma (FFP) at 10-15 mL/kg is given simultaneously to provide an immediate source of functional clotting factors while the vitamin K takes effect. Prothrombin Complex Concentrate (PCC) is reserved for situations where FFP is insufficient or volume overload is a concern.

Step 4: Long-term management. For infants with cholestatic liver disease or chronic malabsorption, a single prophylactic dose of vitamin K at birth is not sufficient. These patients require ongoing oral or parenteral vitamin K supplementation with regular monitoring of PT/INR. This is the most commonly missed point on exams regarding late VKDB prevention: it is not enough to give vitamin K once at birth if the underlying pathology prevents fat-soluble vitamin absorption.

Contraindications and cautions:

• Never give vitamin K by rapid IV push. Always dilute and infuse slowly.

• Recombinant activated factor VII (rFVIIa) is not a standard treatment and should not be chosen over FFP.

• Vitamin K3 (menadione) is a synthetic form that is NOT used in neonates because it causes hemolytic anemia, hyperbilirubinemia, and kernicterus. Only vitamin K1 (phytonadione) is appropriate.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common trap in exam questions about VKDB is confusing it with DIC. Both conditions cause prolonged PT and aPTT in a bleeding neonate, and a student who fixates only on those two values will get stuck. The discriminating factor is always the platelet count and fibrinogen: if they are normal, the answer is VKDB; if they are low (with elevated D-dimer), the answer is DIC. Furthermore, DIC almost always occurs in a clinically ill infant (septic, asphyxiated, or in shock), whereas classic VKDB typically presents in an otherwise well-appearing, exclusively breastfed infant.

A second frequent error involves hemophilia. Students see a bleeding male neonate with a prolonged aPTT and immediately select hemophilia. The giveaway is the PT: if the PT is also prolonged, hemophilia cannot be the answer because hemophilia affects only the intrinsic pathway. VKDB prolongs the PT first and then the aPTT.

A third trap involves the route of vitamin K administration. Students may choose "give vitamin K IM" as the treatment for active bleeding. In a coagulopathic infant, the IM route can cause a large intramuscular hematoma. The correct answer for treatment of active bleeding is slow IV vitamin K, not IM. The IM route is correct only for prophylaxis in a non-bleeding newborn.

A fourth, subtler trap involves late VKDB in infants with cholestatic liver disease (particularly biliary atresia). Even if the infant received IM vitamin K at birth, ongoing malabsorption of fat-soluble vitamins can lead to late VKDB. The vignette clue is an infant aged 4-8 weeks with jaundice (especially pale stools and dark urine suggesting conjugated hyperbilirubinemia) who develops intracranial hemorrhage. The student must recognize that the underlying biliary atresia is the predisposing cause and that ongoing vitamin K supplementation is needed.

Finally, never confuse vitamin K1 (phytonadione) with vitamin K3 (menadione). If an answer choice offers menadione for a neonate, it is always incorrect. Menadione causes oxidative hemolysis and can precipitate severe hyperbilirubinemia and kernicterus.

The core competency being tested is the ability to recognize the classic laboratory pattern (prolonged PT, prolonged aPTT, normal platelets, normal fibrinogen), link it to the clinical context (breastfed neonate, absent prophylaxis, maternal medications), distinguish it from DIC and hemophilia using key discriminators, and select the correct route and formulation for treatment versus prophylaxis.